JP2022530241A5 - - Google Patents
Info
- Publication number
- JP2022530241A5 JP2022530241A5 JP2021564120A JP2021564120A JP2022530241A5 JP 2022530241 A5 JP2022530241 A5 JP 2022530241A5 JP 2021564120 A JP2021564120 A JP 2021564120A JP 2021564120 A JP2021564120 A JP 2021564120A JP 2022530241 A5 JP2022530241 A5 JP 2022530241A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- item
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840810P | 2019-04-30 | 2019-04-30 | |
| PT115483 | 2019-04-30 | ||
| PT11548319 | 2019-04-30 | ||
| US62/840,810 | 2019-04-30 | ||
| PCT/PT2020/050017 WO2020222668A1 (en) | 2019-04-30 | 2020-04-24 | Rank pathway inhibitors in combination with cdk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022530241A JP2022530241A (ja) | 2022-06-28 |
| JP2022530241A5 true JP2022530241A5 (enExample) | 2023-05-08 |
Family
ID=70775461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564120A Pending JP2022530241A (ja) | 2019-04-30 | 2020-04-24 | Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220195059A1 (enExample) |
| EP (1) | EP3962945A1 (enExample) |
| JP (1) | JP2022530241A (enExample) |
| KR (1) | KR20220002316A (enExample) |
| AU (1) | AU2020266083A1 (enExample) |
| BR (1) | BR112021021663A2 (enExample) |
| CA (1) | CA3132656A1 (enExample) |
| MX (1) | MX2021013271A (enExample) |
| WO (1) | WO2020222668A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117062837A (zh) * | 2021-05-12 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 特异性结合rankl和ngf的抗原结合分子及其医药用途 |
| CN115369089A (zh) * | 2022-08-11 | 2022-11-22 | 中山大学孙逸仙纪念医院 | 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途 |
| CN115718192B (zh) * | 2022-11-25 | 2025-02-14 | 浙江洛兮医疗科技有限公司 | 一种免疫组化即用型pd-l1抗体试剂 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US581916A (en) | 1897-05-04 | Harvester | ||
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4342776A (en) | 1979-11-05 | 1982-08-03 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| JPS5839685A (ja) | 1981-09-04 | 1983-03-08 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体及びその製造法 |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| EP0184365B1 (en) | 1984-12-04 | 1993-08-04 | Eli Lilly And Company | Improvements in the treatment of tumors in mammals |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| DK0418099T3 (da) | 1989-09-15 | 2002-04-02 | Res Triangle Inst | Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger |
| FR2707988B1 (fr) | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
| EP1053752A1 (en) | 1998-02-10 | 2000-11-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| AU756796B2 (en) | 1998-10-16 | 2003-01-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Combination therapy with VIP antagonist |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| BR0209774A (pt) | 2001-05-29 | 2004-06-01 | Schering Ag | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento |
| EP2295081B1 (en) | 2001-06-26 | 2018-10-31 | Amgen Inc. | Antibodies to OPGL |
| EP1832589A1 (en) | 2001-10-15 | 2007-09-12 | GPC Biotech Inc. | Inhibitors of cyclin-dependent kinases,compositions and uses related thereto |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| WO2003072062A2 (en) | 2002-02-28 | 2003-09-04 | Temple University-Of The Commonwealth System Of Higher Education | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| US6818663B2 (en) | 2002-05-17 | 2004-11-16 | Hoffmann-La Roches | Diaminothiazoles |
| AU2003279842A1 (en) | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| WO2004069137A2 (de) | 2003-02-07 | 2004-08-19 | Ge Bayer Silicones Gmbh & Co. Kg | Verwendung von polyamino- und/oder polyammonium-polysiloxancopolymeren |
| US20070105100A1 (en) | 2003-04-28 | 2007-05-10 | Canon Kabushiki Kaisha | Process for assay of nucleic acids by competitive hybridization using a dna microarray |
| WO2008130158A1 (en) | 2007-04-19 | 2008-10-30 | Dong-A Pharmaceutical. Co., Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| AU2017271385B2 (en) * | 2016-05-25 | 2023-10-05 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
-
2020
- 2020-04-24 JP JP2021564120A patent/JP2022530241A/ja active Pending
- 2020-04-24 MX MX2021013271A patent/MX2021013271A/es unknown
- 2020-04-24 EP EP20726977.0A patent/EP3962945A1/en not_active Withdrawn
- 2020-04-24 WO PCT/PT2020/050017 patent/WO2020222668A1/en not_active Ceased
- 2020-04-24 KR KR1020217034378A patent/KR20220002316A/ko not_active Ceased
- 2020-04-24 AU AU2020266083A patent/AU2020266083A1/en not_active Abandoned
- 2020-04-24 BR BR112021021663A patent/BR112021021663A2/pt not_active IP Right Cessation
- 2020-04-24 US US17/606,103 patent/US20220195059A1/en not_active Abandoned
- 2020-04-24 CA CA3132656A patent/CA3132656A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530241A5 (enExample) | ||
| TWI821748B (zh) | 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌 | |
| JP2021105001A (ja) | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 | |
| CN110882385B (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| JP2018538274A5 (enExample) | ||
| KR20190015407A (ko) | 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체 | |
| TW202515616A (zh) | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 | |
| US20160347836A1 (en) | Treatment of hodgkin's lymphoma using an anti-pd-1 antibody | |
| JP2020522512A5 (enExample) | ||
| JP2023025036A (ja) | がんの処置のためのアベルマブの投与レジメン | |
| CN113396230A (zh) | 癌症的诊断和治疗方法 | |
| JP2025148452A5 (enExample) | ||
| AU2023232820A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| JP2020507596A (ja) | 膀胱癌の抗ｐｄ−ｌ１抗体治療 | |
| TW201815419A (zh) | Mek抑制劑、 pd-1軸抑制劑及紫杉烷之組合療法 | |
| US20230212292A1 (en) | Use of anti-pd-1 antibody in treating neuroendocrine tumors | |
| JP2015528802A (ja) | フコシル化が低い抗ｈｅｒ２抗体を用いた新規治療処置 | |
| JP7846761B2 (ja) | モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 | |
| TW202309078A (zh) | 治療癌症之方法及組成物 | |
| EP4688854A2 (en) | Methods of treating tumors with anti-tigit antibodies | |
| KR102940576B1 (ko) | Api5 단백질에 특이적으로 결합하는 항체 | |
| US20260034134A1 (en) | Treatment of cancer with metastases in the central nervous system | |
| WO2024216028A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor | |
| CN119630418A (zh) | 抗GARP-TGF-β1/PD-1组合疗法 |